

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

We claim:

Claim 1. (Previously Presented) A process for the preparation of a highly concentrated, liquid formulation comprising monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), comprising ultrafiltrating a preparation comprising said Mab c225 or Mab h425, wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml.

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Previously Presented) The process according to Claim 1, wherein the concentration of said antibody in said highly concentrated, liquid formulation is 100 – 150 mg/ml.

Claim 5. (Cancelled)

Claim 6. (Cancelled)

Claim 7. (Cancelled)

Claim 8. (Previously Presented) A highly concentrated, liquid formulation comprising monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml.

Claim 9. (Cancelled)

Claim 10. (Cancelled)

Claim 11. (Previously Presented) The highly concentrated, liquid formulation according to Claim 8, wherein the concentration of said antibody is 100 – 150 mg/ml.

Claim 12. (Cancelled)

Claim 13. (Cancelled)